$3.39
5.57% today
Nasdaq, Sep 03, 04:50 pm CET
ISIN
US74365N1037
Symbol
PTIX

Protagenic Therapeutics Inc Stock price

$3.59
+0.90 33.46% 1M
-0.28 7.19% 6M
-3.27 47.67% YTD
-4.90 57.70% 1Y
-35.16 90.74% 3Y
-61.93 94.52% 5Y
-862.39 99.59% 10Y
-363,713,276.41 100.00% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.01 0.28%
ISIN
US74365N1037
Symbol
PTIX
Industry

Key metrics

Basic
Market capitalization
$3.1m
Enterprise Value
$2.3m
Net debt
positive
Cash
$870.0k
Shares outstanding
540.0k
Valuation (TTM | estimate)
P/E
negative | -
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
51.8%
Return on Equity
-545.3%
ROCE
5,922.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
$-5.3m | -
EBIT
$-5.3m | -
Net Income
$-5.2m | -
Free Cash Flow
$-3.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
3.6% | -
EBIT
3.5% | -
Net Income
12.8% | -
Free Cash Flow
27.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-10.0
FCF per Share
$-6.7
Short interest
5.3%
Employees
2
Rev per Employee
$0.0
Show more

Is Protagenic Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Protagenic Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Protagenic Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Protagenic Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Protagenic Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 2.05 2.05
86% 86%
-
- Research and Development Expense 3.36 3.36
24% 24%
-
-5.28 -5.28
4% 4%
-
- Depreciation and Amortization 0.05 0.05
25% 25%
-
EBIT (Operating Income) EBIT -5.33 -5.33
3% 3%
-
Net Profit -5.24 -5.24
13% 13%
-

In millions USD.

Don't miss a Thing! We will send you all news about Protagenic Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protagenic Therapeutics Inc Stock News

Neutral
Accesswire
12 days ago
Delay Attributable to Merger-Related Financial Consolidation NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX), a biopharmaceutical company developing novel neuro-active peptide therapies, today announced that it expects to file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 in the near future, following a delay attributable to ...
Neutral
Accesswire
13 days ago
Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026 NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel neuro-active peptide therapies, today announced completion of first dose injection for all study subjects in the multiple-dose portion of its ongoing Phase I clinical t...
Neutral
MCAP MediaWire
about one month ago
NEW YORK, NY and SANTA BARBARA, CA, July 30, 2025 – PRISM MediaWire – Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041.
More Protagenic Therapeutics Inc News

Company Profile

Protagenic Therapeutics, Inc. is a biotechnology company, which engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It offers the PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

Head office United States
Employees 2
Founded 1994
Website protagenic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today